Farringdon Capital’s GSK GSK Stock Holding History

Farringdon Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.86M	Buy	69,914 +23,608	+51%	+$1.28M	0.85%	22
2025 Q4	$2.27M	Buy	+46,306	New	+$2.16M	0.56%	44
2025 Q3	–	Sell	-9,610	Closed	-$369K	–	537
2025 Q2	$369K	Buy	+9,610	New	+$367K	0.12%	277

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Farringdon Capital's GSK Position: Q1 2026 in Review

Farringdon Capital increased its GSK (GSK) stake by 51% in Q1 2026, buying an estimated $1.28M and bringing the position to 69,914 shares worth $3.86M. The position accounts for 0.85% of the portfolio, ranked #22.

Farringdon Capital first reported a position in GSK in Q2 2025 and has held it in 3 quarters since. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Farringdon Capital held 69,914 shares of GSK worth $3.86M as of Q1 2026.
Farringdon Capital bought 23,608 GSK shares in Q1 2026, an estimated $1.28M.
GSK made up 0.85% of Farringdon Capital's portfolio in Q1 2026, its #22 holding.
Farringdon Capital first reported a position in GSK in Q2 2025 and has held it in 3 quarters since.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Farringdon Capital's 13F filing for Q1 2026, filed 15 May 2026.